HUGE Wutah pendapatan triwulanan FSD Pharma

FSD Pharma Inc. (HUGE) is focusing its innovative path on volatile preclinical tests of anti-inflammatory agents. Quarterly commercial revenue growth confirms these fluctuations, with the indicator standing at 0.00. The company is pursuing expansion into CNS therapy through B2B partnerships, yet liquidity shortages and a lack of approved drugs create significant risks to its continued operations.
Rincian metrik lan analitis perusahaan FSD Pharma Inc. (HUGE)
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi pasar:
- rincian valuasi buku bisnis:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas FSD Pharma Inc.|HUGE - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal FSD Pharma Inc.|HUGE - Utang agregat perusahaan|Utang marang nilai buku FSD Pharma Inc.|HUGE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan FSD Pharma|Rasio cepet fsdpharma.com
- indikator bathi lan kelipatan valuasi:
HUGE - Bathi pungkasan|Proyeksi bathi mangsa ngarep FSD Pharma Inc.|HUGE - Pangali P/E|Rega marang bathi mangsa ngarep FSD Pharma|HUGE - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan FSD Pharma Inc.|HUGE - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) FSD Pharma|HUGE - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan fsdpharma.com|HUGE - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep FSD Pharma Inc.
- data pendapatan lan penerimaan dodolan:
HUGE - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan FSD Pharma Inc.|HUGE - Rasio kapitalisasi marang pendapatan|Multiplikator Forward P/S FSD Pharma Inc.|HUGE - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah dodolan triwulanan FSD Pharma|HUGE - Rasio total nilai perusahaan marang pendapatan
- indikator margin:
Pambiji fundamental:FSD Pharma - HUGE

High R&D expenditures coupled with a shortage of internal funds force FSD Pharma Inc. (HUGE) to rely on external financing and reserves. By analyzing quarterly revenue growth, investors track real-deal dynamics to identify a cycle reversal, where a fading uptrend signals a risk of capital impairment amid macroeconomic cooling and phase shifts.
Perusahaan pesaing
JAZZ - Wutah pendapatan kuartal marang kuartal|Tingkat wutah pendapatan sajrone kuartal Cytokinetics|PTCT: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Scholar Rock Corp SRRK|Wutah dodolan triwulanan CNTA|Wutah dodolan kuartal marang kuartal DYN (Dyne Therapeutics, Inc.)|Wutah pendapatan triwulanan EWTX|RAPP (Rapport Therapeutics, Inc.) - Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal Alumis ALMS|Kempharm (ZVRA) - Tingkat wutah pendapatan sajrone kuartal|CTNM - Wutah pendapatan kuartal marang kuartal|Tambahing pendapatan triwulanan LRMR (Larimar Pharma)|Capricor (CAPR) - Wutah pendapatan kuartal marang kuartal|Entrada Therapeutics - Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal Channel|Wutah dodolan triwulanan MediciNova, Inc. (MNOV)|Wutah dodolan triwulanan SER (Serina)|BTAI - Tingkat wutah pendapatan sajrone kuartal|Wutah pendapatan kuartal marang kuartal promisneurosciences.com PMN|Tingkat wutah dodolan sajrone kuartal apimedsus.com (APUS)|AEON - Wutah pendapatan kuartal marang kuartal|Tambahing pendapatan triwulanan NLSP (NLS Pharmaceutics)|Bionomics Limited (BNOX) - Wutah pendapatan kuartal marang kuartal|Reata Pharma (RETA) - Wutah pendapatan triwulanan